Terms: = Breast cancer AND IL6ST, CDw130, 3572, ENSG00000134352, P40189, IL6R-beta, GP130-RAPS, GP130, CD130 AND Treatment
33 results:
1. Impact of disulfidptosis-associated clusters on breast cancer survival rates and guiding personalized treatment.
Chen X; Hu G; Yu Q
Front Endocrinol (Lausanne); 2023; 14():1256132. PubMed ID: 38116315
[TBL] [Abstract] [Full Text] [Related]
2. The clinical relevance of OSM in inflammatory diseases: a comprehensive review.
Wolf CL; Pruett C; Lighter D; Jorcyk CL
Front Immunol; 2023; 14():1239732. PubMed ID: 37841259
[TBL] [Abstract] [Full Text] [Related]
3. Construction of a prognostic model for triple-negative breast cancer based on immune-related genes, and associations between the tumor immune microenvironment and immunological therapy.
Zhu Y; Tao LF; Liu JY; Wang YX; Huang H; Jiang YN; Qian WF
Cancer Med; 2023 Jul; 12(14):15704-15719. PubMed ID: 37306188
[TBL] [Abstract] [Full Text] [Related]
4. Variation in il6st cytokine family function and the potential of IL6 trans-signalling in ERα positive breast cancer cells.
Mosly D; MacLeod K; Moir N; Turnbull A; Sims AH; Langdon SP
Cell Signal; 2023 Mar; 103():110563. PubMed ID: 36565897
[TBL] [Abstract] [Full Text] [Related]
5. Combinational silencing of components involved in JAK/STAT signaling pathway.
Bousoik E; Mahdipoor P; Alhazza A; Montazeri Aliabadi H
Eur J Pharm Sci; 2022 Aug; 175():106233. PubMed ID: 35680032
[TBL] [Abstract] [Full Text] [Related]
6. IL-6 Cytokine Family: A Putative Target for breast cancer Prevention and treatment.
Felcher CM; Bogni ES; Kordon EC
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163731
[TBL] [Abstract] [Full Text] [Related]
7. Bioinformatics Analysis Identifies il6st as a Potential Tumor Suppressor Gene for Triple-Negative breast cancer.
Jia R; Weng Y; Li Z; Liang W; Ji Y; Liang Y; Ning P
Reprod Sci; 2021 Aug; 28(8):2331-2341. PubMed ID: 33650093
[TBL] [Abstract] [Full Text] [Related]
8. Tumors associated with radiotherapy: a case series.
Garcia M; Hernandez DL; Mendoza S; Buelvas N; Alvarez A; Esguerra J; Díaz S
J Med Case Rep; 2020 Oct; 14(1):179. PubMed ID: 33019945
[TBL] [Abstract] [Full Text] [Related]
9. Coinhibition of S1PR1 and gp130 by siRNA-loaded alginate-conjugated trimethyl chitosan nanoparticles robustly blocks development of cancer cells.
Rostami N; Nikkhoo A; Khazaei-Poul Y; Farhadi S; Sadat Haeri M; Moghadaszadeh Ardebili S; Aghaei Vanda N; Atyabi F; Namdar A; Baghaei M; Haghnavaz N; Kazemi T; Yousefi M; Ghalamfarsa G; Sabz G; Jadidi-Niaragh F
J Cell Physiol; 2020 Dec; 235(12):9702-9717. PubMed ID: 32424937
[TBL] [Abstract] [Full Text] [Related]
10. miR-188-5p suppresses cellular proliferation and migration via il6st: A potential noninvasive diagnostic biomarker for breast cancer.
Wang M; Zhang H; Yang F; Qiu R; Zhao X; Gong Z; Yu W; Zhou B; Shen B; Zhu W
J Cell Physiol; 2020 May; 235(5):4890-4901. PubMed ID: 31650530
[TBL] [Abstract] [Full Text] [Related]
11. Bazedoxifene is a novel IL-6/gp130 inhibitor for treating triple-negative breast cancer.
Tian J; Chen X; Fu S; Zhang R; Pan L; Cao Y; Wu X; Xiao H; Lin HJ; Lo HW; Zhang Y; Lin J
Breast Cancer Res Treat; 2019 Jun; 175(3):553-566. PubMed ID: 30852762
[TBL] [Abstract] [Full Text] [Related]
12. Intraoperative Resection Guidance with Photoacoustic and Fluorescence Molecular Imaging Using an Anti-B7-H3 Antibody-Indocyanine Green Dual Contrast Agent.
Wilson KE; Bachawal SV; Willmann JK
Clin Cancer Res; 2018 Aug; 24(15):3572-3582. PubMed ID: 29712688
[No Abstract] [Full Text] [Related]
13. Neoadjuvant palbociclib on ER+ breast cancer (N007): clinical response and EndoPredict's value.
Chow LWC; Morita S; Chow CYC; Ng WK; Toi M
Endocr Relat Cancer; 2018 Feb; 25(2):123-130. PubMed ID: 29158285
[TBL] [Abstract] [Full Text] [Related]
14. Inhibition of IL-6/STAT3 signaling in human cancer cells using Evista.
Shi W; Yan D; Zhao C; Xiao M; Wang Y; Ma H; Liu T; Qin H; Zhang C; Li C; Lin J; Li S; Lv J; Lin L
Biochem Biophys Res Commun; 2017 Sep; 491(1):159-165. PubMed ID: 28711499
[TBL] [Abstract] [Full Text] [Related]
15. Identification of genes and pathways related to lymphovascular invasion in breast cancer patients: A bioinformatics analysis of gene expression profiles.
Klahan S; Wong HS; Tu SH; Chou WH; Zhang YF; Ho TF; Liu CY; Yih SY; Lu HF; Chen SC; Huang CC; Chang WC
Tumour Biol; 2017 Jun; 39(6):1010428317705573. PubMed ID: 28651487
[TBL] [Abstract] [Full Text] [Related]
16. Potential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancer.
Heo TH; Wahler J; Suh N
Oncotarget; 2016 Mar; 7(13):15460-73. PubMed ID: 26840088
[TBL] [Abstract] [Full Text] [Related]
17. Increasing Use of Neoadjuvant treatment for T1 and T2 HER2-Positive Tumors.
Al-Hilli Z; Boughey JC; Hoskin TL; Heins CN; Hieken TJ
Ann Surg Oncol; 2015 Oct; 22(10):3369-75. PubMed ID: 26202564
[TBL] [Abstract] [Full Text] [Related]
18. Analysis of gene expression of secreted factors associated with breast cancer metastases in breast cancer subtypes.
Fertig EJ; Lee E; Pandey NB; Popel AS
Sci Rep; 2015 Jul; 5():12133. PubMed ID: 26173622
[TBL] [Abstract] [Full Text] [Related]
19. Accurate Prediction and Validation of Response to Endocrine Therapy in breast cancer.
Turnbull AK; Arthur LM; Renshaw L; Larionov AA; Kay C; Dunbier AK; Thomas JS; Dowsett M; Sims AH; Dixon JM
J Clin Oncol; 2015 Jul; 33(20):2270-8. PubMed ID: 26033813
[TBL] [Abstract] [Full Text] [Related]
20. Optimisation of steroid prophylaxis schedules in breast cancer patients receiving docetaxel chemotherapy-a survey of health care providers and patients.
Jacobs C; Hutton B; Mazzarello S; Smith S; Joy A; Amir E; Ibrahim MF; Gregario N; Daigle K; Eggert L; Clemons M
Support Care Cancer; 2015 Nov; 23(11):3269-75. PubMed ID: 25933700
[TBL] [Abstract] [Full Text] [Related]
[Next]
